Life Extension Skin Care Sale

Obesity and Weight Loss References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. American Heart Association. Statistical Fact Sheet 2012 update; Overweight and Obesity. Available at: accessed 1/9/0212.
  2. Stevens GA, Singh GM, Lu Y, Danaei G, Lin JK, Finucane MM, . . . Ezzati M. National, regional, and global trends in adult overweight and obesity prevalences. Population health metrics. Nov 20 2012;10(1):22.
  3. Aleksandrova K, Nimptsch K, Pischon T. Obesity and colorectal cancer. Frontiers in bioscience. 2013;5:61-77.
  4. Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, . . . Maclean PS. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer research. Dec 15 2012;72(24):6490-6501.
  5. Allott EH, Masko EM, Freedland SJ. Obesity and Prostate Cancer: Weighing the Evidence. European urology. Nov 15 2012.
  6. Gribovskaja-Rupp I, Kosinski L, Ludwig KA. Obesity and colorectal cancer. Clinics in colon and rectal surgery. Dec 2011;24(4):229-243.
  7. Schrager, M. A., Metter, E. J., Simonsick, E., et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 2007;102(3):919–25.
  8. Sung, M.-K., Yeon, J.-Y., Park, S.-Y., Park, J. H. Y., and Choi, M.-S. Obesity-induced metabolic stresses in breast and colon cancer. Ann N Y Acad Sci. 2011;1229:61–8.
  9. Nguyen, N. T., Magno, C. P., Lane, K. T., Hinojosa, M. W., and Lane, J. S. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J. Am. Coll. Surg. 2008;207(6):928–34.
  10. CDC. Centers for Disease Control and Prevention. Prevalence of obesity among adults with arthritis --- United States, 2003--2009. MMWR. Morbidity and mortality weekly report. Apr 29 2011;60(16):509-513.
  11. Sassi F and Devaux M. The Organisation for Economic Co-operation and Development (OECD); Obesity Update 2012. Available at: . Accessed 1/8/2013.
  12. Cohen, D. A., and Bhatia, R. Nutrition standards for away-from-home foods in the USA. Obes Rev. 2012;13(7):618–29
  13. Müssig, K., Remer, T., and Maser-Gluth, C. Brief review: glucocorticoid excretion in obesity. J. Steroid Biochem. Mol. Biol. 2010;121(3-5):589–93
  14. Biondi, B. Thyroid and obesity: an intriguing relationship. J Clin Endocrinol Metab. 2010;95(8):3614–7
  15. Marieb, E., and Hoehn, K. Human anatomy & physiology. 8th ed. © 2010. San Francisco: Pearson Benjamin Cummings.  
  16. Begg, D. P., and Woods, S. C. The central insulin system and energy balance. Handb Exp Pharmacol. 2012;(209):111–29
  17. Myers MG Jr, Leibel RL, Seeley RJ, et al. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010;21(11):643-51.
  18. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens, Greece). Jan-Mar 2012;11(1):8-20.
  19. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature medicine. Aug 2001;7(8):941-946.
  20. Kadowaki T, Yamauchi T, Waki H, Iwabu M, Okada-Iwabu M, Nakamura M. Adiponectin, adiponectin receptors, and epigenetic regulation of adipogenesis. Cold Spring Harbor symposia on quantitative biology. 2011;76:257-265.
  21. Siasos G, Tousoulis D, Kollia C, Oikonomou E, Siasou Z, Stefanadis C, Papavassiliou AG. Adiponectin and cardiovascular disease: mechanisms and new therapeutic approaches. Current medicinal chemistry. 2012;19(8):1193-1209.
  22. Brusik M, Ukropec J, Joppa P, Ukropcova B, Skyba P, Balaz M, . . . Tkacova R. Circulatory and adipose tissue leptin and adiponectin in relationship to resting energy expenditure in patients with chronic obstructive pulmonary disease. Physiological research / Academia Scientiarum Bohemoslovaca. Aug 8 2012.
  23. Hunter GR, Weinsier RL, Gower BA, Wetzstein C. Age-related decrease in resting energy expenditure in sedentary white women: effects of regional differences in lean and fat mass. The American journal of clinical nutrition. Feb 2001;73(2):333-337.
  24. Bosy-Westphal A, Eichhorn C, Kutzner D, Illner K, Heller M, Muller MJ. The age-related decline in resting energy expenditure in humans is due to the loss of fat-free mass and to alterations in its metabolically active components. The Journal of nutrition. Jul 2003;133(7):2356-2362.
  25. Hill, J. O., Wyatt, H. R., and Peters, J. C. Energy balance and obesity. Circulation. 2012;126(1):126–32
  26. Paolisso, G., Tagliamonte, M. R., Rizzo, M. R., and Giugliano, D. Advancing age and insulin resistance: new facts about an ancient history. Eur J Clin Invest. 1999;29(9):758–69
  27. AoA Statistics, F. I. F. O. A.-R. Older Americans 2008: key indicators of well-being. Washington, DC: US Government Printing Office. Available at: Main Site/Data/2008 Documents/OA 2008. pdf.
  28. Vincent, H. K., Vincent, K. R., and Lamb, K. M. Obesity and mobility disability in the older adult. Obes Rev. 2010;11(8):568–79
  29. Apostolopoulou, M., Savopoulos, C., Michalakis, K., Coppack, S., Dardavessis, T., and Hatzitolios, A. Age, weight and obesity. Maturitas. 2012;71(2):115–9
  30. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA : the journal of the American Medical Association. Nov 10 2004;292(18):2243-2248.
  31. Wu, F. C. W., Tajar, A., Pye, S. R., et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737–45
  32. Mårin, P. Testosterone and regional fat distribution. Obes. Res. 1995;3 Suppl 4:609S–612S
  33. Kaufman, J. M., and Vermeulen, A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 2005;26(6):833–76
  34. Vermeulen, A., Kaufman, J. M., Goemaere, S., and van Pottelberg, I. Estradiol in elderly men. Aging Male. 2002;5(2):98–102
  35. Williams, G. Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling. Mol Cell Endocrinol. 2012;351(2):269–78
  36. Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., and Salpeter, E. E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538–54
  37. Mayes, J. S., and Watson, G. H. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev. 2004;5(4):197–216
  38. Norman, R. J., Flight, I. H., and Rees, M. C. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev. 2000;(2):CD001018
  39. Asvold, B. O., Bjøro, T., and Vatten, L. J. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab. 2009;94(12):5023–7
  40. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, and Mahaffey KR. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid. 2007;17(12):1211–23
  41. Rotondi, M., Magri, F., and Chiovato, L. Thyroid and obesity: not a one-way interaction. J Clin Endocrinol Metab. 2011;96(2):344–6
  42. National Diabetes Information Clearinghouse (NDIC). Insulin Resistance and Prediabetes. Updated 12/6/11. Available at: Accessed 1/4/2012.
  43. Hagobian, T. A., and Braun, B. Physical activity and hormonal regulation of appetite: sex differences and weight control. Exerc Sport Sci Rev. 2010;38(1):25–30
  44. Ortega Martinez de Victoria, E., Xu, X., Koska, J., et al. Macrophage content in subcutaneous adipose tissue: associations with adiposity, age, inflammatory markers, and whole-body insulin action in healthy Pima Indians. Diabetes. 2009;58(2):385–93
  45. Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., and Ferrante, A. W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808
  46. Despres JP. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. Diabetes & metabolism. Sep 2003;29(4 Pt 2):6S53-61.
  47. Berstein LM. Metformin in obesity, cancer and aging: addressing controversies. Aging (Albany NY). May 2012;4(5):320-329.
  48. Jéquier E. Pathways to obesity. Int. J. Obes. Relat. Metab. Disord. 2002;26 Suppl 2:S12–7
  49. Chen, K., Li, F., Li, J., et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat. Med. 2006;12(4):425–32
  50. Yu Y, Hu SK, Yan H. [The study of insulin resistance and leptin resistance on the model of simplicity obesity rats by curcumin]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. Nov 2008;42(11):818-822.
  51. Shao W, Yu Z, Chiang Y, Yang Y, Chai T, Foltz W, . . . Jin T. Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PloS one. 2012;7(1):e28784.
  52. Selenscig D, Rossi A, Chicco A, Lombardo YB. Increased leptin storage with altered leptin secretion from adipocytes of rats with sucrose-induced dyslipidemia and insulin resistance: effect of dietary fish oil. Metabolism: clinical and experimental. Jun 2010;59(6):787-795.
  53. Tsitouras PD, Gucciardo F, Salbe AD, Heward C, Harman SM. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. Mar 2008;40(3):199-205.
  54. Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids in health and disease. 2009;8:7.
  55. Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids in health and disease. 2008a;7:44.
  56. Swinburn, B., Sacks, G., and Ravussin, E. Increased food energy supply is more than sufficient to explain the US epidemic of obesity. American Journal of Clinical Nutrition. 2009;90(6):1453–6
  57. Kant, A. K., and Graubard, B. I. Eating out in America, 1987-2000: trends and nutritional correlates. Prev Med. 2004;38(2):243–9
  58. Rolls, B. J., Roe, L. S., and Meengs, J. S. Larger portion sizes lead to a sustained increase in energy intake over 2 days. J Am Diet Assoc. 2006;106(4):543–9
  59. Nielsen, S. J., and Popkin, B. M. Patterns and trends in food portion sizes, 1977-1998. JAMA. 2003;289(4):450–3
  60. Vinson, J. A., Burnham, B. R., and Nagendran, M. V. Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes. 2012;5:21–7
  61. McClendon KS, Riche DM, Uwaifo GI. Orlistat: current status in clinical therapeutics. Expert opinion on drug safety. Nov 2009;8(6):727-744.
  62. Smith TJ, Crombie A, Sanders LF, Sigrist LD, Bathalon GP, McGraw S, Young AJ. Efficacy of orlistat 60 mg on weight loss and body fat mass in US Army soldiers. Journal of the Academy of Nutrition and Dietetics. Apr 2012;112(4):533-540.
  63. Blaak EE, Antoine JM, Benton D, Bjorck I, Bozzetto L, Brouns F, . . . Vinoy S. Impact of postprandial glycaemia on health and prevention of disease. Obesity reviews : an official journal of the International Association for the Study of Obesity. Oct 2012;13(10):923-984.
  64. Strojek K, Majkowska L, Zozulinska D, Gumprecht J, Krzymien J, Malecki M. [Postprandial glycemia--review of current pathophysiological, epidemiological and clinical aspects]. Polskie Archiwum Medycyny Wewnetrznej. May-Jun 2007;117(5-6):252-259.
  65. Sahade V, Franca S, Badaro R, Fernando Adan L. Obesity and postprandial lipemia in adolescents: risk factors for cardiovascular disease. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion. Feb 2012;59(2):131-139.
  66. Jackson KG, Poppitt SD, Minihane AM. Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants. Atherosclerosis. Jan 2012;220(1):22-33.
  67. Sargent, B. J., and Moore, N. A. New central targets for the treatment of obesity. Br J Clin Pharmacol. 2009;68(6):852–60
  68. Lam, D. D., Garfield, A. S., Marston, O. J., Shaw, J., and Heisler, L. K. Brain serotonin system in the coordination of food intake and body weight. Pharmacology, Biochemistry and Behavior. 2010;97(1):84–91
  69. Ioannides-Demos, L. L., Piccenna, L., and McNeil, J. J. Pharmacotherapies for obesity: past, current, and future therapies. J Obes. 2011;2011:179674
  70. Breum L, Rasmussen MH, Hilsted J, Fernstrom JD. Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. The American journal of clinical nutrition. May 2003;77(5):1112-1118.
  71. De Vriendt, T., Moreno, L. A., and De Henauw, S. Chronic stress and obesity in adolescents: scientific evidence and methodological issues for epidemiological research. Nutr Metab Cardiovasc Dis. 2009;19(7):511–9
  72. Björntorp, P. Metabolic implications of body fat distribution. Diabetes Care. 1991;14(12):1132–43
  73. Fried, S. K., Russell, C. D., Grauso, N. L., and Brolin, R. E. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest. 1993;92(5):2191–8
  74. Björntorp, P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2(2):73–86
  75. Torres, S. J., and Nowson, C. A. Relationship between stress, eating behavior, and obesity. Nutrition. 2007;23(11-12):887–94
  76. Hartaigh O, Bosch JA, Carroll D, Hemming K, Pilz S, Loerbroks A, . . . Thomas GN. Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography. European heart journal. Nov 23 2012.
  77. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, . . . Czernichow S. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. American journal of epidemiology. Jan 1 2013;177(1):3-13.
  78. Cruz NG, Sousa LP, Sousa MO, Pietrani NT, Fernandes AP, Gomes KB. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes research and clinical practice. Dec 13 2012.
  79. Holmes C. Systemic inflammation and Alzheimer's Disease. Neuropathology and applied neurobiology. Oct 10 2012.
  80. Trayhurn, P., and Wood, I. S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 2005;33(Pt 5):1078–81
  81. Mohamed-Ali, V., Goodrick, S., Rawesh, A., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196–200
  82. Zhang, Y., Daquinag, A., Traktuev, D. O., et al. White Adipose Tissue Cells Are Recruited by Experimental Tumors and Promote Cancer Progression in Mouse Models. Cancer Res. 2009;69(12):5259–66
  83. Brown, K. A., and Simpson, E. R. Obesity and breast cancer: mechanisms and therapeutic implications. Front Biosci (Elite Ed). 2012;4:2515–24
  84. Li, Q., Zhang, J., Zhou, Y., and Qiao, L. Obesity and gastric cancer. Front Biosci. 2012;17:2383–90
  85. Shen, C., Zhao, C.-Y., Zhang, R., and Qiao, L. Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity. Front Biosci. 2012;17:2356–70
  86. Jaffe T and Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer. 2008;123(11):2543–56
  87. Fröhlich, E., and Wahl, R. Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types? Diabetes Obes Metab. 2012;14(3):204–13
  88. Mijovic, T., How, J., and Payne, R. J. Obesity and thyroid cancer. Front Biosci (Schol Ed). 2011;3:555–64
  89. Bastard, J.-P., Maachi, M., Lagathu, C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006;17(1):4–12
  90. Kones, R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther. 2010;4:383–413
  91. Emerging Risk Factors Collaboration, Kaptoge, S., Di Angelantonio, E., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40
  92. Schnohr, P. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12000 men and women from The Copenhagen City Heart Study. European Heart Journal. 2002;23(8):620–6
  93. Nguyen, T., and Lau, D. C. W. The obesity epidemic and its impact on hypertension. Can J Cardiol. 2012b;28(3):326–33
  94. Naumnik B, Mysliwiec M. Renal consequences of obesity. Medical science monitor : international medical journal of experimental and clinical research. Aug 2010;16(8):RA163-170.
  95. The Trials of Hypertension Prevention Collaborative Research Group 1997
  96. He, J., Whelton, P. K., Appel, L. J., Charleston, J., and Klag, M. J. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35(2):544–9
  97. Jiang, L., Tian, W., Wang, Y., et al. Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysis. Joint Bone Spine. 2012;79(3):291–7
  98. Vakil, N., van Zanten, S. V., Kahrilas, P., Dent, J., Jones, R., Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. In, p. 1900–20; quiz1943.
  99. Festi, D., Scaioli, E., Baldi, F., et al. Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol. 2009;15(14):1690–701
  100. Hampel, H., Abraham, N. S., and El-Serag, H. B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211
  101. Akinnusi, M. E., Saliba, R., Porhomayon, J., and El-Solh, A. A. Sleep disorders in morbid obesity. Eur. J. Intern. Med. 2012;23(3):219–26
  102. Knutson KL, Spiegel K, Penev P, Van Cauter E. The metabolic consequences of sleep deprivation. Sleep medicine reviews. Jun 2007;11(3):163-178.
  103. Benedict C, Brooks SJ, O'Daly OG, Almen MS, Morell A, Aberg K, . . . Schioth HB. Acute sleep deprivation enhances the brain's response to hedonic food stimuli: an fMRI study. The Journal of clinical endocrinology and metabolism. Mar 2012;97(3):E443-447.
  104. Expert Panel on the Identification Evaluation and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr. 1998;68(4):899–917
  105. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. 2000.
  106. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. 1998.
  107. Prentice, A. M., and Jebb, S. A. Beyond body mass index. Obes Rev. 2001;2(3):141–7
  108. Thomas, J.-A., and Freedland, S. J. Obesity and prostate cancer: collateral damage in the battle of the bulge. Front Biosci (Schol Ed). 2011;3:594–605
  109. Owen CG, Whincup PH, Orfei L, Chou QA, Rudnicka AR, Wathern AK, . . . Cook DG. Is body mass index before middle age related to coronary heart disease risk in later life? Evidence from observational studies. International journal of obesity. Aug 2009;33(8):866-877.
  110. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. The American journal of gastroenterology. Nov 2006;101(11):2619-2628.
  111. Shah NR, Braverman ER. Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PloS one. 2012;7(4):e33308.
  112. Mayo Clinic. Obesity; Treatments and Drugs. Available at: Updated 8/3/2012. Accessed 12/31/2012.
  113. Xiao D, Shi D, Yang D, Barthel B, Koch TH, Yan B. Carboxylesterase-2 Is a Highly Sensitive Target of the Antiobesity Agent Orlistat with Profound Implications in the Activation of Anticancer Prodrugs. Biochemical pharmacology. Dec 7 2012.
  114. Rucker, D., Padwal, R., Li, S. K., Curioni, C., and Lau, D. C. W. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194–9
  115. Garber, A. J. Obesity and type 2 diabetes: which patients are at risk? Diabetes Obes Metab. 2012;14(5):399–408
  116. Healy, M. FDA approves lorcaserin, first weight-loss drug since 1999. 2012; Available at: [Accessed October 14, 2012].
  117. Houck L. DEA Proposes Controlling Lorcaserin in Schedule IV. 12/20/2012. Available at: Accessed 12/22/2012.
  118. Gann, C. FDA Approves Weight Loss Drug Qsymia. 2012; Available at: [Accessed October 15, 2012].
  119. Cameron, F., Whiteside, G., and McKeage, K. Phentermine and topiramate extended release (qsymia™): first global approval. Drugs. 2012;72(15):2033–42
  120. Hiatt, W. R., Thomas, A., and Goldfine, A. B. What cost weight loss? Circulation. 2012;125(9):1171–7
  121. Dixon, J. B., le Roux, C. W., Rubino, F., and Zimmet, P. Bariatric surgery for type 2 diabetes. Lancet. 2012;379(9833):2300–11
  122. Gersin, K. S., Keller, J. E., Stefanidis, D., et al. Duodenal- jejunal bypass sleeve: a totally endoscopic device for the treatment of morbid obesity. Surg Innov. 2007;14(4):275–8
  123. Nguyen, N., Champion, J. K., Ponce, J., et al. A review of unmet needs in obesity management. Obes Surg. 2012a;22(6):956–66
  124. Molavi, B., Rassouli, N., Bagwe, S., and Rasouli, N. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Vasc Health Risk Manag. 2007;3(6):967–73
  125. Buler, M., Aatsinki, S.-M., Skoumal, R., et al. Energy-sensing Factors Coactivator Peroxisome Proliferator-activated Receptor γ Coactivator 1-α (PGC-1α) and AMP-activated Protein Kinase Control Expression of Inflammatory Mediators in Liver: INDUCTION OF INTERLEUKIN 1 RECEPTOR ANTAGONIST. J Biol Chem. 2012;287(3):1847–60
  126. Dhahbi, J. M., Mote, P. L., Fahy, G. M., and Spindler, S. R. Identification of potential caloric restriction mimetics by microarray profiling. Physiol Genomics. 2005;23(3):343–50
  127. Hanefeld, M., Cagatay, M., Petrowitsch, T., Neuser, D., Petzinna, D., and Rupp, M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. European Heart Journal. 2004;25(1):10–6
  128. Van de Laar, F. A., Lucassen, P. L. B. J., Akkermans, R. P., Van de Lisdonk, E. H., Rutten, G. E. H. M., and Van Weel, C. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;(2):CD003639
  129. LANE, M., BLACK, A., and INGRAM, D. Calorie restriction in nonhuman primates: implications for age-related disease risk. Journal of Anti-Aging …. 1998; 1(4): 315-326
  130. Walford, R. L., Mock, D., Verdery, R., and MacCallum, T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J Gerontol A Biol Sci Med Sci. 2002;57(6):B211–24
  131. Fontana, L., Meyer, T. E., Klein, S., and Holloszy, J. O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA. 2004;101(17):6659–63
  132. Fontana, L., Klein, S., Holloszy, J. O., and Premachandra, B. N. Effect of long-term calorie restriction with adequate protein and micronutrients on thyroid hormones. J Clin Endocrinol Metab. 2006;91(8):3232–5
  133. Meyer, T. E., Kovács, S. J., Ehsani, A. A., Klein, S., Holloszy, J. O., and Fontana, L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. 2006;47(2):398–402
  134. Lefevre M, Redman LM, Heilbronn LK, et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009;203(1):206-13.
  135. Calton, J. B. Prevalence of micronutrient deficiency in popular diet plans. J Int Soc Sports Nutr. 2010;7:24
  136. King, N. A., Horner, K., Hills, A. P., et al. Exercise, appetite and weight management: understanding the compensatory responses in eating behaviour and how they contribute to variability in exercise-induced weight loss. Br J Sports Med. 2012;46(5):315–22
  137. Maarbjerg, S. J., Sylow, L., and Richter, E. A. Current understanding of increased insulin sensitivity after exercise - emerging candidates. Acta Physiol (Oxf). 2011;202(3):323–35
  138. Hebden, L., Chey, T., and Allman-Farinelli, M. Lifestyle intervention for preventing weight gain in young adults: a systematic review and meta-analysis of RCTs. Obes Rev. 2012;13(8):692–710
  139. Stehr, M. D., and Lengerke, von, T. Preventing weight gain through exercise and physical activity in the elderly: a systematic review. Maturitas. 2012;72(1):13–22
  140. Dennis, E. A., Flack, K. D., and Davy, B. M. Beverage consumption and adult weight management: A review. Eat Behav. 2009;10(4):237–46
  141. Onakpoya, I., Terry, R., and Ernst, E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011;2011:
  142. Lopez-Garcia, E., van Dam, R. M., Rajpathak, S., Willett, W. C., Manson, J. E., and Hu, F. B. Changes in caffeine intake and long-term weight change in men and women. Am J Clin Nutr. 2006;83(3):674–80
  143. Bakuradze, T., Boehm, N., Janzowski, C., et al. Antioxidant-rich coffee reduces DNA damage, elevates glutathione status and contributes to weight control: Results from an intervention study. Mol. Nutr. Food Res. 2011;55(5):793–7
  144. Thom, E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J. Int. Med. Res. 2007;35(6):900–8
  145. Singh, R., Akhtar, N., and Haqqi, T. M. Green tea polyphenol epigallocatechin-3-gallate: inflammation and arthritis. [corrected]. Life Sci. 2010;86(25-26):907–18
  146. Hooper, L., Kroon, P. A., Rimm, E. B., et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition. 2008;88(1):38–50
  147. Johnson, R., Bryant, S., and Huntley, A. L. Green tea and green tea catechin extracts: An overview of the clinical evidence. Maturitas. 2012 Dec;73(4):280-7
  148. Hursel, R., Viechtbauer, W., and Westerterp-Plantenga, M. S. The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int J Obes (Lond). 2009;33(9):956–61
  149. Phung, O. J., Baker, W. L., Matthews, L. J., Lanosa, M., Thorne, A., and Coleman, C. I. Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. American Journal of Clinical Nutrition. 2010;91(1):73–81
  150. Maeda, H., Hosokawa, M., Sashima, T., Funayama, K., and Miyashita, K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun. 2005;332(2):6–6
  151. D'Orazio, N., Gemello, E., Gammone, M. A., de Girolamo, M., Ficoneri, C., and Riccioni, G. Fucoxantin: a treasure from the sea. Mar Drugs. 2012;10(3):604–16
  152. Abidov, M., Ramazanov, Z., Seifulla, R., and Grachev, S. The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab. 2010;12(1):72–81
  153. Marik, P. E., and Varon, J. Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol. 2009;32(7):365–72
  154. Geleijnse, J. M., Giltay, E. J., Grobbee, D. E., Donders, A. R. T., and Kok, F. J. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens. 2002;20(8):1493–9
  155. Li J-J, Huang CJ, Xie D. Anti-obesity effects of conjugated linoleic acid, docosahexaenoic acid, and eicosapentaenoic acid. Molecular Nutrition & Food Research. 2008;52(6):631-45.
  156. Hill, A. M., Buckley, J. D., Murphy, K. J., and Howe, P. R. C. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. Am J Clin Nutr. 2007;85(5):1267–74
  157. Thorsdottir, I., Tomasson, H., Gunnarsdottir, I., et al. Randomized trial of weight-loss-diets for young adults varying in fish and fish oil content. Int J Obes (Lond). 2007;31(10):1560–6
  158. Ahuja, K. D. K., and Ball, M. J. Effects of daily ingestion of chilli on serum lipoprotein oxidation in adult men and women. Br J Nutr. 2006;96(2):239–42
  159. Luo, X.-J., Peng, J., and Li, Y.-J. Recent advances in the study on capsaicinoids and capsinoids. European Journal of Pharmacology. 2011;650(1):1–7
  160. Hursel, R., and Westerterp-Plantenga, M. S. Thermogenic ingredients and body weight regulation. Int J Obes (Lond). 2010;34(4):659–69
  161. Egras, A. M., Hamilton, W. R., Lenz, T. L., and Monaghan, M. S. An evidence-based review of fat modifying supplemental weight loss products. J Obes. 2011;2011
  162. Ngondi, J. L., Oben, J. E., and Minka, S. R. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids Health Dis. 2005;4:12
  163. Oben, J. E., Ngondi, J. L., Momo, C. N., Agbor, G. A., and Sobgui, C. S. M. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis. 2008b;7:12
  164. Devalaraja, S., Jain, S., and Yadav, H. Exotic fruits as therapeutic complements for diabetes, obesity and metabolic syndrome. Food Research International. 2011;44(7):1856–6
  165. Galani, V. J., Patel, B. G., and Rana, D. G. Sphaeranthus indicus Linn.: A phytopharmacological review. Int J Ayurveda Res. 2010;1(4):247–53
  166. Lau, F. C., Golakoti, T., Krishnaraju, A. V., and Sengupta, K. Efficacy and tolerability of Merastin™- A randomized, double-blind, placebo-controlled study. FASEB J. 2011;25:601Lefevre, M., Redman, L. M., Heilbronn, L. K., et al. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis. 2009;203(1):206–13
  167. Wolfe, B. E., Metzger, E. D., and Stollar, C. The effects of dieting on plasma tryptophan concentration and food intake in healthy women. Physiol Behav. 1997;61(4):537–41
  168. Hrboticky, N., Leiter, L. A., and Anderson, G. H. Effects of L-tryptophan on short term food intake in lean men. Nutrition Research. 1985;5(6):595–607
  169. Cavaliere, H., and Medeiros-Neto, G. The anorectic effect of increasing doses of L-tryptophan in obese patients. Eat Weight Disord. 1997 Dec;2(4):211-5.
  170. Gout, B., Bourges, C., and Paineau-Dubreuil, S. Satiereal, a Crocus sativus L extract, reduces snacking and increases satiety in a randomized placebo-controlled study of mildly overweight, healthy women. Nutr Res. 2010;30(5):305–13
  171. Hughes GM, Boyland EJ, Williams NJ, Mennen L, Scott C, Kirkham TC, . . . Halford JC. The effect of Korean pine nut oil (PinnoThin) on food intake, feeding behaviour and appetite: a double-blind placebo-controlled trial. Lipids in health and disease. 2008;7:6.
  172. Yamaguchi, T., Chikama, A., and Mori, K. Hydroxyhydroquinone-free coffee: A double-blind, randomized controlled dose-response study of blood pressure. Nutr Metab Cardiovasc Dis. 2008 Jul;18(6):408-414.
  173. Ho L, Varghese M, Wang J, Zhao W, Chen F, Knable LA, . . . Pasinetti GM. Dietary supplementation with decaffeinated green coffee improves diet-induced insulin resistance and brain energy metabolism in mice. Nutritional neuroscience. Jan 2012;15(1):37-45.
  174. Nagendran MV. Effect of Green Coffee Bean Extract (GCE), High in chlorogenic acids, on glucose metabolism. Poster presentation number: 45-LB-P. Obesity 2011, the 29th annual scientific meeting of the obesity society. Orlando, Florida. October 1-5, 2011.
  175. Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC complementary and alternative medicine. 2006;6:9.
  176. Arion WJ, Canfield WK, Ramos FC, Schindler PW, Burger HJ, Hemmerle H, . . . Herling AW. Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. Archives of biochemistry and biophysics. Mar 15 1997;339(2):315-322.
  177. Henry-Vitrac C, Ibarra A, Roller M, Merillon JM, Vitrac X. Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. Journal of agricultural and food chemistry. Apr 14 2010;58(7):4141-4144.
  178. Gerstein HC, Pais P, Pogue J, Yusuf S. Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. Journal of the American College of Cardiology. Mar 1999;33(3):612-619.
  179. Paradis, M.-E., Couture, P., and Lamarche, B. A randomised crossover placebo-controlled trial investigating the effect of brown seaweed (Ascophyllum nodosum and Fucus vesiculosus) on postchallenge plasma glucose and insulin levels in men and women. Appl Physiol Nutr Metab. 2011;36(6):913–9
  180. Preuss, H. G. Bean amylase inhibitor and other carbohydrate absorption blockers: effects on diabesity and general health. J Am Coll Nutr. 2009;28(3):266–76
  181. Barrett, M. L., and Udani, J. K. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): a review of clinical studies on weight loss and glycemic control. Nutr J. 2011;10:24
  182. Seri K, Sanai K, Matsuo N, Kawakubo K, Xue C, Inoue S. L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. Metabolism. 1996 Nov;45(11):1368-74.
  183. Osaki S, Kimura T, Sugimoto T, Hizukuri S, Iritani N. L-arabinose feeding prevents increases due to dietary sucrose in lipogenic enzymes and triacylglycerol levels in rats. J Nutr. 2001 Mar;131(3):796-9.
  184. Preuss HG, Echard B, Bagchi D, Stohs S. Inhibition by natural dietary substances of gastrointestinal absorption of starch and sucrose in rats and pigs: 1. Acute studies. Int J Med Sci. 2007a;4(4):196-202.
  185. Preuss HG, Echard B, Bagchi D, Stohs S. Inhibition by natural dietary substances of gastrointestinal absorption of starch and sucrose in rats 2. Subchronic studies. Int J Med Sci. 2007b;4(4):209-15.
  186. Doi, K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr. 1995;49 Suppl 3:S190–7
  187. Sood, N., Baker, W. L., and Coleman, C. I. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. American Journal of Clinical Nutrition. 2008;88(4):1167–75
  188. Doi K, Nakamura T, Aoyama N, Matsurura M, Kawara A, Baba S. Metabolic and nutritional effects of long-term use of glucomannan in the treatment of obesity. In: Oomura Y, ed. Progress in Obesity Research. John Libbey & Company, Ltd., 1990:507-14.
  189. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10(3):319-29.
  190. Heffner, K. L. Neuroendocrine effects of stress on immunity in the elderly: implications for inflammatory disease. Immunol Allergy Clin North Am. 2011;31(1):95–108
  191. Weiss EP, Villareal DT, Fontana L, et al. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging (Albany NY). 2011;3(5):533-42.
  192. Ihler, G., and Chami-Stemmann, H. 7-oxo-DHEA and Raynaud's phenomenon. Med. Hypotheses. 2003;60(3):391–7
  193. Bobyleva, V., Bellei, M., Kneer, N., and Lardy, H. The effects of the ergosteroid 7-oxo-dehydroepiandrosterone on mitochondrial membrane potential: possible relationship to thermogenesis. Arch. Biochem. Biophys. 1997;341(1):122–8
  194. Kalman DS, Colker CM, et al. A randomized, double-blind, placebo-controlled study of 3-acetyl-oxo-dehydroepiandrosterone in healthy overweight adults. Curr Ther Res. 2000;61(7):435-42.
  195. Zenk, J. L., Frestedt, J. L., and Kuskowski, M. A. HUM5007, a novel combination of thermogenic compounds, and 3-acetyl-7-oxo-dehydroepiandrosterone: each increases the resting metabolic rate of overweight adults. J Nutr Biochem. 2007;18(9):629–34
  196. Davidson, M., Marwah, A., Sawchuk, R. J., et al. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. Clin Invest Med. 2000;23(5):300–10
  197. Barbero-Becerra VJ, Santiago-Hernandez JJ, Villegas-Lopez FA, Mendez-Sanchez N, Uribe M, Chavez-Tapia NC. Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. Current medicinal chemistry. 2012;19(18):2918-2923.
  198. De Maddalena C, Vodo S, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. Journal of cellular physiology. Dec 2012;227(12):3744-3748.
  199. Champagne, C. M. Magnesium in hypertension, cardiovascular disease, metabolic syndrome, and other conditions: a review. Nutrition in Clinical Practice. 2008;23(2):142–51
  200. Chacko, S. A., Sul, J., Song, Y., et al. Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals. American Journal of Clinical Nutrition. 2011;93(2):463–73
  201. Liu, S., Choi, H. K., Ford, E., et al. A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care. 2006;29(7):1579–84
  202. Juhel C, Armand M, Pafumi Y, Rosier C, Vandermander J, Lairon D. Green tea extract (AR25) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro. The Journal of nutritional biochemistry. Jan 2000;11(1):45-51.
  203. Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. The Journal of nutritional biochemistry. Mar 2007;18(3):179-183.
  204. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. The Journal of nutrition. Sep 2008;138(9):1677-1683.
  205. Lee MS, Kim CT, Kim IH, Kim Y. Inhibitory effects of green tea catechin on the lipid accumulation in 3T3-L1 adipocytes. Phytotherapy research : PTR. Aug 2009;23(8):1088-1091.
  206. Chen YK, Cheung C, Reuhl KR, Liu AB, Lee MJ, Lu YP, Yang CS. Effects of green tea polyphenol (-)-epigallocatechin-3-gallate on newly developed high-fat/Western-style diet-induced obesity and metabolic syndrome in mice. Journal of agricultural and food chemistry. Nov 9 2011;59(21):11862-11871.
  207. Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine : international journal of phytotherapy and phytopharmacology. Jan 2002;9(1):3-8.